Anixa Biosciences (ANIX) News Today $3.12 -0.05 (-1.42%) As of 01:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Anixa Biosciences (NASDAQ:ANIX) Given "Buy" Rating at HC WainwrightFebruary 20 at 1:43 AM | americanbankingnews.comAnixa Biosciences (NASDAQ:ANIX) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday.February 19 at 4:08 PM | marketbeat.comAnixa Biosciences, Inc.: Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical TrialFebruary 19 at 12:23 AM | finanznachrichten.deAnixa Biosciences announces approval of protocol amendment for CAR-T trialFebruary 19 at 12:23 AM | markets.businessinsider.comAnixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical TrialFebruary 18 at 8:00 AM | prnewswire.comShort Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Expands By 13.7%Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 403,100 shares, an increase of 13.7% from the January 15th total of 354,500 shares. Based on an average daily volume of 121,000 shares, the short-interest ratio is presently 3.3 days. Approximately 1.3% of the shares of the stock are short sold.February 15, 2025 | marketbeat.comAnixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading InterviewFebruary 14, 2025 | prnewswire.comAnixa Biosciences to Present at the 18th Annual European Life Sciences CEO ForumFebruary 11, 2025 | prnewswire.comAnixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer PreventionFebruary 4, 2025 | prnewswire.comAnixa Biosciences, Inc. (CY71.F)February 2, 2025 | ca.finance.yahoo.comAnixa biosciences director Arnold Baskies buys $14,100 in stockJanuary 29, 2025 | msn.comArnold M. Baskies Purchases 5,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies bought 5,000 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were purchased at an average price of $2.82 per share, for a total transaction of $14,100.00. Following the completion of the acquisition, the director now owns 120,000 shares of the company's stock, valued at $338,400. The trade was a 4.35 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.January 29, 2025 | marketbeat.comAnixa Biosciences director Titterton buys $8,820 in common stockJanuary 27, 2025 | msn.comAnixa Biosciences director Lewis Titterton buys $6,020 worth of stockJanuary 23, 2025 | msn.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $15,540.00 in StockJanuary 23, 2025 | insidertrades.comAnixa Biosciences director Lewis H. Titterton Jr. buys $15,540 in stockJanuary 23, 2025 | msn.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Purchases 6,000 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. bought 6,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were acquired at an average cost of $2.59 per share, for a total transaction of $15,540.00. Following the purchase, the director now directly owns 928,334 shares in the company, valued at $2,404,385.06. This represents a 0.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.January 22, 2025 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday.January 22, 2025 | marketbeat.comAnixa Biosciences reports progress in cancer vaccine trialsJanuary 21, 2025 | msn.comAnixa Biosciences CEO Provides Letter to ShareholdersJanuary 21, 2025 | prnewswire.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Acquires 10,000 SharesJanuary 18, 2025 | insidertrades.comAnixa biosciences director Lewis Titterton buys shares worth $25,700January 17, 2025 | msn.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $25,700.00 in StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. bought 10,000 shares of the company's stock in a transaction on Friday, January 17th. The stock was bought at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the acquisition, the director now directly owns 922,334 shares of the company's stock, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.January 17, 2025 | marketbeat.comAnixa Biosciences Leads 3 Promising Penny Stocks On US ExchangesJanuary 17, 2025 | finance.yahoo.comAnixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires $19,971.35 in StockJanuary 16, 2025 | insidertrades.comAnixa Biosciences (ANIX) Projected to Post Quarterly Earnings on TuesdayAnixa Biosciences (NASDAQ:ANIX) will be releasing earnings before the market opens on Tuesday, January 21, Financial Modeling Prep reports.January 15, 2025 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani Acquires 9,289 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CFO Michael Catelani bought 9,289 shares of the stock in a transaction on Wednesday, January 15th. The shares were bought at an average price of $2.15 per share, for a total transaction of $19,971.35. Following the acquisition, the chief financial officer now owns 44,500 shares in the company, valued at $95,675. The trade was a 26.38 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.January 15, 2025 | marketbeat.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Buys 43,000 Shares of StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar purchased 43,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 15th. The stock was bought at an average cost of $2.23 per share, with a total value of $95,890.00. Following the completion of the transaction, the chief executive officer now directly owns 559,925 shares of the company's stock, valued at $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 15, 2025 | marketbeat.comAnixa Biosciences' (ANIX) "Buy" Rating Reaffirmed at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday.January 14, 2025 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth PlansJanuary 14, 2025 | finance.yahoo.comAnixa Biosciences (NASDAQ:ANIX) Announces Earnings Results, Beats Expectations By $0.02 EPSAnixa Biosciences (NASDAQ:ANIX - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02.January 11, 2025 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 10.3% in NovemberAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 369,000 shares, a decline of 10.3% from the November 15th total of 411,600 shares. Approximately 1.2% of the company's shares are sold short. Based on an average daily volume of 89,100 shares, the short-interest ratio is presently 4.1 days.December 15, 2024 | marketbeat.comAnixa Biosciences: Uncertainty In The Pipeline, Uncertainty In Their Financial OutlookDecember 10, 2024 | seekingalpha.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Shares Could Be 20% Below Their Intrinsic Value EstimateDecember 4, 2024 | uk.finance.yahoo.comAnixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10December 4, 2024 | prnewswire.comAnixa Biosciences board approves purchase of Bitcoin as treasury reserve assetNovember 23, 2024 | markets.businessinsider.comAnixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve AssetNovember 22, 2024 | prnewswire.comAnixa Biosciences Gains Buy Rating from Yi Chen Amid Promising Cancer Therapy AdvancesNovember 20, 2024 | markets.businessinsider.comAnixa Biosciences' (ANIX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday.November 19, 2024 | marketbeat.comAnixa Biosciences initiates third cohort in CAR-T clinical trialNovember 18, 2024 | markets.businessinsider.comAnixa Biosciences, Inc.: Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical TrialNovember 18, 2024 | finanznachrichten.deAnixa Hikes on TestsNovember 18, 2024 | baystreet.caAnixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical TrialNovember 18, 2024 | prnewswire.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in OctoberAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 421,900 shares, a decline of 28.9% from the October 15th total of 593,700 shares. Based on an average daily volume of 75,800 shares, the short-interest ratio is presently 5.6 days. Approximately 1.4% of the company's shares are sold short.November 14, 2024 | marketbeat.comAnixa Biosciences Reports Promising Phase 1 Vaccine ResultsNovember 9, 2024 | markets.businessinsider.comAnixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 8, 2024 | prnewswire.comAnixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 6, 2024 | prnewswire.comAnixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024October 31, 2024 | prnewswire.comAnixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingOctober 28, 2024 | prnewswire.comAnixa Biosciences administers second CAR-T dose in ovarian cancer trialOctober 16, 2024 | finance.yahoo.com Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIX Media Mentions By Week ANIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIX News Sentiment▼0.360.60▲Average Medical News Sentiment ANIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIX Articles This Week▼82▲ANIX Articles Average Week Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Astria Therapeutics News Aura Biosciences News Phathom Pharmaceuticals News Chimerix News Oruka Therapeutics News Atai Life Sciences News Revance Therapeutics News Prime Medicine News Esperion Therapeutics News REGENXBIO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIX Stock Alerts